ArticleOncotarget2016

Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism.

Shuai Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.